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Abstract
Background: Research involving adults who lack the capacity to provide informed consent can be challenging. In
England and Wales there are legal provisions for consulting with others who know the person with impaired
capacity. The role of the ‘proxy’ (or ‘surrogate’) is to advise researchers about the person’s wishes and feelings or to
provide consent on the person’s behalf for a clinical trial of a medicine. Information about the study is usually
provided to the proxy; however, little information is available to proxies about their role, or the appropriate legal
and ethical basis for their decision, to help inform their decision-making. The aim of this study was to analyse the
written information that is provided to consultees and legal representatives.
Methods: Studies including adults lacking capacity to consent which utilised consultees or legal representatives were
identified using the UK Clinical Trials Gateway database. A representative sample (n = 30) were randomly selected.
Information sheets and other study documents provided to proxies were obtained, and relevant content was extracted.
Content analysis was conducted through four stages: decontextualisation of the unit of analysis, recontextualisation,
categorisation, and compilation. The data were summarised narratively according to each theme and category.
Results: Considerable variation was found in the written information sheets provided to proxies. Most directed proxies
to consider the wishes and feelings of the person who lacked capacity and to consult with others during the decision-
making process. However, a small number of studies extended the scope of the proxy’s role to consider the person’s
suitability or eligibility for the study. Particular discrepancies were found in information provided to those acting as
consultees or legal representatives in a professional, as opposed to a personal, capacity. Incorrect uses of terminology
were frequently found, and a small number of studies inaccurately interpreted the law.
Conclusions: Despite undergoing ethical review, study documents lacked essential information, incorrectly used
terminology, and conflated professionals’ clinical and representation roles. Future recommendations include ensuring
proxies are provided with adequate and accurate information which complies with the legal frameworks. Further research
is needed to explore the information and decision-making needs of those acting as consultees and legal representatives.
Keywords: Informed consent, mental capacity, proxy, content analysis, participant information sheets, randomised
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Background
Informed consent is fundamental to ethically conducted
medical research [1], but obtaining valid consent can be
particularly challenging in specific practice contexts [2].
Individuals may be unable to provide consent for them-
selves due to an impairing medical condition that strikes
suddenly (like a stroke) or causes a gradual loss of cap-
acity (such as dementia) or due to profound learning
disabilities. The exclusion of those who lack mental cap-
acity from participating in research has been highlighted
as a concern [3], as it results in a lack of evidence-based
care for populations who may already experience signifi-
cant health disparities [4].
In England and Wales the Mental Capacity Act 2005
(MCA) has provision for consulting an individual who
knows the person with impaired capacity well, such as a
family member, to advise about research participation on
the person’s behalf [5]. The consultee is provided with
information about the project and asked what the poten-
tial participant’s likely wishes and feelings would be
about taking part in the project if he or she had capacity
[5]. Any indication that the person would not have
wished to participate must be respected [5]. Responsibil-
ity for deciding whether to include a person lacking cap-
acity lies ultimately with the researcher [5]. Clinical
trials of investigational medicinal products (CTIMPs)
are regulated separately in the UK under the Medicines
for Human Use (Clinical Trials) Regulations 2004 (CTR)
[6], although this is shortly to be replaced with the Clin-
ical Trials Regulation No 536/2014 [7]. Under the CTR,
the relative or friend acting as legal representative must
decide whether the person lacking capacity should par-
ticipate in the trial on the basis of what they would have
wanted had they the capacity to choose for themselves,
their ‘presumed will’ [6]. The legal representative must
be given the opportunity to understand the objectives,
risks, and inconveniences of the trial, and then provides
informed consent on behalf of the person who lacks cap-
acity [6]. Should no appropriate relative or friend be
available or willing to act as the person’s ‘proxy’ or ‘sur-
rogate’, under both the MCA and CTR there are provi-
sions for a professional to act as a nominated consultee
(s32(2)) [5, 8] or legal representative (Schedule 1, Part
1(2(a)(ii))) [6]. The term proxy is used in this paper to
include both consultees and legal representatives acting
in either a personal or professional capacity.
Written information about the study is tailored for
proxies, usually in the form of an amended version of
the information provided to participants themselves. If a
person is willing to act as proxy, he/she will then be
asked to provide written confirmation of his/her advice
regarding the person’s wishes [5] or informed consent
on that person’s behalf [6] using a consent or declaration
form. Proxy versions of participant information sheets
(PISs) and consent or declaration forms are not standar-
dised, and there is minimal guidance available for re-
searchers when drafting documents for studies involving
adults lacking capacity, although templates are available
[9]. Neither the MCA nor the CTR have requirements
regarding the information that should be given to the
person acting as proxy about his/her role, only concern-
ing information about the project [5] or the objectives,
risks, and inconveniences of the trial and the conditions
under which it is to be conducted [6]. There is no guid-
ance for proxies about how their decision should be
made or what to do if they are unable to determine what
the person would have wanted. Decision-making may be
challenging for proxies. Preferences regarding future
participation in research are rarely discussed and, for in-
dividuals who have never held relevant views and prefer-
ences, they will be impossible to determine. Proxies are
acutely aware of the moral difference between deciding
for oneself and deciding for others. They report that de-
cisions about research participation are burdensome
[10], and they experience varying degrees of comfort and
confidence in proxy decision-making. Many studies have
empirically evaluated the readability and content of PISs
and consent forms [11–15] and assessed participant
comprehension [16]. However, no studies have examined
written information provided to proxies.
Documents can be considered as socially situated
products which are produced, consumed, and used in
organised settings, and understanding how they function
is important [17]. Content analysis is an empirically
grounded research method [18] which has been de-
scribed as providing a ‘systematic and objective means to
make valid inferences from verbal, visual, or written data
in order to describe and quantify specific phenomena’
(p. 314) [18]. Content analysis has been used in a range
of academic disciplines, including social and healthcare
sciences, and has been applied to a variety of data and to
various depths of interpretation, using both qualitative
and quantitative methodology [19].
This study aimed to explore the written information
provided to proxies who have been approached to be in-
volved in decision-making about research participation for
an adult who lacks the capacity to provide his/her own
consent. The information that related specifically to the
proxy’s role was reviewed, rather than information about
the study per se. Attention was paid to the context in
which the documents were used: the type of research and
study population, information about why the proxy had
been approached (including whether they were
approached in a personal or professional capacity), the
proxy’s role in the decision-making process, the required
basis for the proxy’s decision, and any information or
guidance about how the proxy might approach the deci-
sion including any sources of guidance or support. The
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correct legal basis was determined by reference to the le-
gislation governing research involving adults lacking cap-
acity in England and Wales, the MCA [5], and CTR [6].
Methods
Sampling
Current or recently completed (within the preceding 3
years) studies were identified from the National Institute
for Health Research (NIHR) co-ordinated UK Clinical Tri-
als Gateway (UKCTG) public database (formerly the NIHR
Portfolio database). Studies which included participants
aged 16+ years who may lack decision-making capacity,
and therefore require proxy involvement, were eligible for
inclusion. Whilst capacity is considered decision-specific ra-
ther than global and is not a static construct [5], the cir-
cumstances under which a proxy decision-maker is
required and the proxy’s prior experience of acting as
decision-maker are relevant factors in this context. The
UKCTG is primarily intended for patients to find relevant
clinical trials to participate in, and so the database uses
condition-specific search terms, in addition to filters such
as trial status. Therefore studies which included adults who
lacked capacity were identified by searching the database
for appropriate medical conditions or populations which
are more likely to be associated with cognitive impairment.
Studies which involved emergency research, and therefore a
consent waiver, were excluded.
A search strategy was designed to include trials con-
ducted in different decisional contexts through classifying
the circumstances under which proxy involvement is re-
quired, either as part of a progressive process, following a
sudden or acute event, or to reflect long-term circum-
stances. This necessitated a pragmatic search strategy
which identified condition-specific search terms (as re-
quired by the UKCTG) that would capture trials across
these three areas. It is recognised that a lack of capacity
cannot be established by reference to a condition [5], and
only some individuals living with these conditions will ex-
perience any cognitive impairment or impaired capacity
specific to the particular enrolment decision. Searches
were conducted in June and July 2017 by one researcher
(VS) using search terms agreed by three researchers (VS,
FW, KH). Search terms to identify eligible studies were di-
vided between three groups of decisional contexts:
 Progressive process: search terms ‘dementia’
(all types), ‘Huntington’s Disease’
 Sudden or acute event: search terms ‘stroke’,
‘traumatic brain injury’, ‘critical care’
 Long-term circumstances: search terms ‘Down’s
syndrome’, ‘intellectual disability’, ‘learning disability’
All types of research designs were included. A sample of
30 studies was randomly selected from the list of eligible
studies, stratified by the three groups of decisional con-
text. In content analysis, there are no established criteria
for the number of sampling units or objects to study; the
sample size is based on the informational needs and the
ability to answer the research question with confidence
[20]. The sample size estimation for this analysis was de-
rived from a similar study examining consent forms for
clinical genetic content [15].
All study documents provided to the proxy were ob-
tained through the UKCTG database links (funder or
sponsor’s website, study website, etc.) or were requested
from the lead investigator, project co-ordinator, or spon-
sor as appropriate. Studies were only eligible if study
documents were available. Where study documents
could not be obtained, the study was considered to be
ineligible, and a replacement study was randomly se-
lected from the same condition/group. Sampling contin-
ued until the target sample was reached.
Data collection
The sampling unit for inclusion was the study; the unit
of analysis was the documents provided to proxies to
provide information to help inform their
decision-making for each study. These documents in-
cluded proxy/participant information sheets, informed
consent or declaration forms, or other relevant docu-
ments. Studies were allocated a unique reference num-
ber and anonymised to remove any identifiable
information. Study documents were reviewed and ana-
lysed for content relating to the role of the proxy and
the decision about research participation, and the area
of interest data extracted. The respective numbers and
types of documents were recorded by individual study
and per group (progressive loss of capacity, acute loss of
capacity, no prior capacity).
Content analysis
Content analysis can take many forms [17, 19]. This
study was conducted using a pragmatic content analysis
approach [17], incorporating both quantitative and
qualitative analyses. Content areas, defined as parts of
the text that address a specific topic, were identified and
extracted. Content was divided into that which informed
the proxy as to why they had been approached, the basis
for their decisions, how the proxy might approach mak-
ing a decision, practical instructions to be followed, and
information about withdrawal from the study. The ana-
lysis process followed that outlined by Bengtsson [20] as
a series of iterative steps, with the four main stages being
decontextualisation of the unit of analysis, recontextuali-
sation, categorisation, and compilation. The meaning
unit (or coding or content unit) was defined as words,
sentences, or paragraphs containing aspects related to
each other through their content and context [19].
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The documents were reviewed in order to ensure familiar-
ity with the text, and the content areas from the study docu-
ments were extracted and entered into qualitative data
analysis software (NVivo 11). During the decontextualisation
stage the meaning unit (the words or sentences that are
intended to convey an item of information or instruction to
the proxy about their role or decision) was coded using a
coding framework agreed between three researchers (VS,
FW, KH). The data were coded iteratively by one researcher
(VS), with discussion with the research team to increase the
stability and reliability of the coding process. Sample data ex-
tracts were regularly reviewed by the group to ensure
consistency of coding.
During the recontextualisation stage, the meaning
units were re-read alongside the original data to ensure
the content was adequately captured, with no extraneous
data included that were not relevant to the aim of the
study [20]. For the categorisation stage, the themes and
categories emerging from the meaning units were identi-
fied. There are no universally adopted concepts for the
headings used in content analysis [20]; however, themes
were the broader overall concepts, and the categories
were the smaller sub-themes that brought together a
number of related meaning units.
The compilation stage drew on a manifest level of ana-
lysis, which stays very close to the original text to describe
what was said using the visible and obvious [21]. Given the
nature of data contained in these types of documents, a
manifest analysis which stays closer to the original meaning
and context was considered to be appropriate. The data
were summarised narratively according to each theme and
category. A summary of themes and categories was tabu-
lated, with illustrative meaning units presented. The themes
and categories were quantified to allow a greater represen-
tation of information [20].
Results
Of 1194 potentially eligible studies identified, 70 studies
(6%) included adults lacking capacity. Study documents
could not be obtained for 15 studies, because either there
were no viable contact details for the study or there was no
response from the study team. There were no refusals.
Sampling ceased when documents had been obtained for a
total of 30 studies, which were subsequently included in the
review (Table 1). An additional file shows the study charac-
teristics in more detail (Additional file 1). Studies included
both observational and interventional studies, of which 9
(30%) were classified as a CTIMP. The majority of studies
were sponsored either by a higher education institute (n =
19, 63%) or by a National Health Service (NHS) organisa-
tion (n = 10, 33%). The NIHR was the funding body in 22
studies (73%), followed by charitable funders (n = 7, 23%).
Studies were either currently ongoing (n = 14, 47%) or had
been completed within the previous 3 years (n = 16, 53%).
Studies primarily combined information about the
proxy’s role with information about the study itself into
a single document (n = 28, 93%), although two studies
had separate documents for the role of the proxy and
the study information which was contained in the stand-
ard PIS (study ID 04, ID 12). Consequently, study infor-
mation sheets ranged considerably in length (Table 2).
Where the information sheet combined information
about the proxy’s role and the study, the area of interest
that related to the proxy’s role (area of interest/total
length of document) comprised 7–68% of the total
length of the document.
Studies were divided into those that provided separate
documents for proxies acting in a personal capacity
(relative or friend as a personal consultee or personal
legal representative) and a professional capacity (mem-
ber of the care team as a nominated consultee or
Table 1 Characteristics of screened and included studies by decisional context
Decisional context Search term/conditiona No. studies
identified
No. potentially
eligibleb studies
No. studies
included
No. CTIMPsc
included
Study IDs
Long-term circumstances Down’s syndrome 181 9 4 1 01–04
Intellectual disability
Learning disability
Progressive process Alzheimer’s disease 505 33 12 1 05–16
Dementia
Huntingdon’s disease
Care home(s)
Sudden/acute event Critical care 508 28 14 7 17–30
Acute stroke
Traumatic brain injury
Total 1194 70 30 9
aSearch terms are filters or categories used by the UKCTG to enable users to search for clinical trials by condition or disease area
bEligible if study documents are available (all other eligibility criteria having been met)
cNumber of clinical trials of investigational medicinal products (CTIMPs) included
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professional legal representative) (n = 10, 33%), those
with joint documents for both personal and professional
proxies (n = 9, 30%), studies that provided documents
for personal proxies only (n = 8, 27%), or where it was
assumed that there was no provision for professional
proxies as information sheets were not provided for pro-
fessional proxies (n = 3, 10%).
Content relating to why the proxy was being
approached was found in all 42 study documents. Con-
tent relating to other categories of information varied
considerably, with only 13 documents (31%) providing
information about how the proxy might approach
decision-making (Table 3).
Key themes
Representing the wishes, feelings, and interests of the
person with impaired capacity
Almost all studies advised or directed proxies to con-
sider the wishes and feelings using standard phrases
such as ‘You are being asked to advise the researchers
about this person’s wishes and feelings’. Some extended
this to advising on the person’s views about taking part
in research in general or the particular study in question,
using phrases such as ‘you may be aware of any views
they may have about taking part in such a project’.
With the exception of two, studies made no reference
to the temporal aspects of the person’s wishes and feel-
ings — whether the proxy should consider their past or
presently expressed wishes, and the comparative weight
that should be afforded to current and prior wishes
should they conflict. The two study documents that did
include temporal considerations stated that proxies
should base their advice on their knowledge of their
friend/relative and both ‘their past and present views or
feelings’ (ID 12, ID 14). The MCA uses the future condi-
tional tense to require the proxy to consider ‘what the
person’s wishes and feelings about taking part in the
project would be likely to be if they had capacity in rela-
tion to the matter’ (s32(4b)) [5]. The CTR provide less
guidance, merely that the informed consent given ‘shall
represent that adult’s presumed will’ (Schedule 1, Part 5,
Principle 12) [6]. Some study documents extended the
proxy’s role to consider the interests, as well as the
wishes and feelings, of the person, which reflects the
Table 2 Quantitative data from study information sheets
Total no. of documents
n = 42 (%)
Unit size by no. words
range (median)
Total length of document 42 217–3997 (1665)
CTIMP 14 217–2676 (2067)
Non-CTIMP 28 230–3997 (1602)
Total area of interest 42 79–926 (344)
Proportion of total length of document (area of interest/total length of document) 79/1197–641/953
7–68%
CTIMP 14 79–371 (232)
Non-CTIMP 28 155–926 (422)
Why the proxy is being approached 42 (100%) 22–494 (104)
CTIMP 14 22–217 (122)
Non-CTIMP 28 27–494 (98)
Basis for the decision 38 (90%) 8–267 (83)
CTIMP 10 14–123 (51)
Non-CTIMP 28 8–267 (107)
How the proxy might approach deciding 13 (31%) 18–185 (67)
CTIMP 1 76
Non-CTIMP 12 18–185 (66)
Practical instructions for the proxy 38 (90%) 18–309 (80)
CTIMP 10 18–151 (75)
Non-CTIMP 28 28–309 (83)
Withdrawal from the study (including proxy’s role) 34 (81%) 19–168 (44)
CTIMP 11 25–87 (49)
Non-CTIMP 23 19–168 (43)
CTIMP Clinical trial of an investigational medicinal product, governed by CTR
Non-CTIMP Research other than a clinical trial of an investigational medicinal product, governed by MCA
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phrasing used in the template developed by the UK
Health Research Authority (HRA) [7]. One study listed
the following factors the proxy should consider: the aims
of the research, previous thoughts and wishes, risks and
benefits to the patient and others, how being involved
with the research would affect the patient’s routine, and
any advance decisions about participating in research
the patient may have made (ID 15). One study advised
the professional representative to ensure that there were
no other known factors (e.g. cultural or religious beliefs)
which may influence whether the patient would want to
participate in medical research (ID 19).
Some study documents directed which perspective or
viewpoint the proxy was expected to take, by advising the
proxy to disregard his/her own views when making a deci-
sion: ‘it is important that you should set aside any of your
own personal views about the project’ or ‘your views of re-
search in general’ (ID 02, ID 06, ID 12, ID 14, ID 22).
Consulting with others
A number of the study documents (n = 16) included ad-
vising or directing the proxy to consult with others dur-
ing the decision-making process, phrased as either
talking to others if wished or if necessary. Some speci-
fied whom might be consulted: other relatives, friends,
or healthcare professionals, although professionals were
advised to restrict this to ‘other colleagues who have an
interest in the person’s welfare, but who won’t be in-
volved in the research themselves’ (ID 12). Although
there is no specific requirement to consult others under
either the MCA or CTR, the general principle of the
MCA is to consult others who are engaged in caring for
the person or interested in the person’s welfare when de-
cisions are made about research participation (s4(7b))
[5]. If the proxy was uncertain about taking on the role,
eight studies advised that he/she could seek independent
advice, although no information was provided about
how or where that advice could be obtained. A small
number advised the proxy to consult with the person
themselves, phrased as to ‘attempt’ or ‘try to’ seek the
views of the person. These were all from studies involv-
ing care home residents (ID 12, ID 13, ID 14).
Consultee’s role
Some of the non-CTIMP studies made it clear that the
consultee was not being asked to provide consent on the
person’s behalf, as would be the case if they were a legal
representative in a CTIMP. This was either explicitly stated
in the description of the proxy’s role: ‘A personal consultee
is not asked to provide consent for or on behalf of their
relative/friend’ (ID 12) or implicit in the description of the
proxy’s role being to ‘give advice’ about the person’s wishes
(ID 04). In some documents where this statement was in-
cluded, the wrong terminology was sometimes still used:
Table 3 Content examples by category
Why the proxy is being approached
We would like to invite your relative/friend to be part of a research
study. We feel that he/she may not be able to decide for himself/herself
whether to participate in this research. We would therefore like to ask
your opinion as to whether or not you think he/she would want to be
involved (personal consultee information sheet ID 214)
We would like to invite one of your residents to take part in our research
study. We feel that they are unable to decide for themselves whether to
participate in this research. To help decide if he/she should join the study,
we would like to ask your opinion about whether you think they would
want to be involved (nominated consultee information sheet ID 218)
We are asking you, as a [title of medical role] or [title of medical role], to
consider whether you will be able to act as a professional legal
representative to provide agreement for your patient to participate in
the [name of trial]. The majority of patients who will be eligible for this
trial, due to the severity of their injuries, will not have capacity to
provide informed consent for enrolment into the trial (professional legal
representative information sheet ID 306)
Basis for the decision
You are being asked to advise the researchers about this person’s wishes and
feelings as to whether they themselves would have wished to join this
research (personal consultee information sheet ID 105)
If you agree please read the information sheet carefully and give your opinion as
to whether or not you think this patient would be willing to participate in this
medical research (professional legal representative information sheet ID 311)
How the proxy might approach deciding
Using what you know of the wishes and feelings of your relative/friend,
please advise us on whether you feel he/she would have agreed to join
the study, if he/she had been able to decide for him/herself. Please base
your advice on your knowledge of your relative/friend and their past and
present views or feelings, not on your own views of research in general or
this project. You should try to seek the views of your relative/friend, if
appropriate, and also the views of other family or friends in helping give
this advice (personal consultee information sheet ID 213)
If you have known them for some time, you may be aware of any views they
may have about taking part in such a project or whether they have made an
‘Advance Decision’. If the potential participant has made an ‘Advance Decision’
this is important, as it shows that they have already made decisions for
themselves (professional legal representative information sheet ID 105)
Think about the broad aims of the research, the risks and benefits, and
what taking part will mean for this person (combined personal and
nominated consultee information sheet ID 203)
Practical instructions for the proxy
If you are prepared to act as the consultee you will be provided with a
copy of the participant information sheet and be given an opportunity to
discuss the project with one of the researchers so that you can form an
opinion as to the individual’s likely wishes/feelings with respect to the
project. If, at the end of this process, you feel that the individual would like
to take part in the project, you will be asked to sign a form to that effect
(personal consultee information sheet ID 108)
Please take time to read the following information carefully. Talk to others
about the study if you wish. Ask us if there is anything that is not clear to
you, or if you would like more information. Take time to decide whether or
not you wish the patient to take part. If you do decide for them to take
part, you will be given this information sheet to keep and be asked to sign
a consent form (professional legal representative information sheet ID 316)
Withdrawal from the study
If the resident does take part in the research, we will keep you fully
informed during the study so you can let us know if you have any
concerns or you think the resident no longer wishes to take part
(nominated consultee information sheet ID 214)
If you later decide that he/she no longer wishes to take part, please
inform us and he/she will be withdrawn from the study. You do not
need to give a reason and it will not affect the standard of care your
relative receives (personal consultee information sheet ID 317)
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‘After appropriate consultation we would like you to
complete the attached consent form indicating whether you
feel the named person would or would not have wished to
participate’ (ID 14), and ‘The consultee does not give con-
sent, only advice’ followed by ‘We would also like to seek
your consent so that any remaining samples may be stored
and used in possible future research’ (ID 28) although this
is not required [22]. Only one non-CTIMP study directly
stated that the responsibility to decide whether the partici-
pant should be entered into the research lies ultimately
with the researcher (ID 16).
Extension of proxy’s role to include determining eligibility
A small number of studies appeared to extend the scope
of the proxy’s role beyond that of representing the per-
son’s wishes or feelings about participation, or their pre-
sumed will. One document provided to personal
consultees had the option for the consultee to decline
the study on behalf of the person if they did not consider
that their relative/friend was ‘well enough to take part’
(ID 12). The role of professionals acting as legal repre-
sentative was sometimes extended to determining the
person’s eligibility for the study, either explicitly (ID 19,
ID 27) or implicitly by confirming that they understand
‘what the study involves, including inclusion and exclu-
sion criteria’ (ID 30). Eligibility forms part of the investi-
gator’s role; the role of the professional legal
representative is to represent the person’s wishes and
feelings as someone who is unconnected to the study.
Advance decisions
Some studies asked proxies to inform the researchers
about any advance decisions the person may have made,
as these ‘should take’ or ‘will take’ precedence (ID 02, ID
25). Others extended the scope to ‘any advance decisions
they may have made about participating in research’ (ID
11, ID 13, ID 15, ID 22, ID 26), which reflects the wording
used in the HRA template [9]. The MCA has provisions
for Advance Decisions to Refuse Treatment (ADRT)
which relate to refusal rather than a positive request, and
it refers to medical treatment decisions rather than those
about research [5]. The MCA Code of Practice states ‘Re-
searchers must not do anything the person who lacks cap-
acity objects to. They must not do anything to go against
any advance decision to refuse treatment or other state-
ment the person has previously made expressing prefer-
ences about their care or treatment’ (s11.30) [23]. This
means the researcher has an obligation to respect the per-
son’s expression of refusal that may conflict with participa-
tion in a research study, where the care/treatment is part
of the intervention or associated requirements.
Inaccurate use of terminology
There were many instances of confusion in the use of
the terms for the proxy, where the proxy was called a
‘legal representative’ when the study did not fall under
the scope of the CTR and therefore the proper term
should have been ‘consultee’, or the term ‘consultee’ was
used when the MCA was not the governing legislation
and the proxy was therefore acting as a legal representa-
tive. A combination of terms was used for proxies in
some studies (‘professional consultee’ ID 17), and alter-
native terms were introduced in some studies: ‘inde-
pendent physician’ and ‘proxy relative’ (ID 27) and
‘Registered Medical Practitioner’ (ID 30). The term
‘assent’ was used in three studies (ID 12, ID 14, ID 22)
either in the information sheet provided to the proxy or
in the title of the document. Assent is not a recognised
term in legislation governing research involving adults in
England and Wales, although it is a legally recognised
term in paediatric research, and is used informally by
some research professionals when referring to the in-
volvement of adults who lack capacity to consent.
The term ‘consent’ was used when the process was in fact
consultation (ID 18, ID 22) or where the consultee declar-
ation form required the ‘Name of Person taking consent’
(ID 03). The opposite was also observed, where informed
consent should have been obtained from the legal represen-
tative, but the documents referred to ‘consultation’ and
‘consultee’ (ID 26) or ‘declaration’ as illustrated by ‘We will
seek written informed consent from the patient, or declar-
ation from a personal legal representative, as soon as pos-
sible after the patient’s admission’ (ID 19).
Disconnect between information provided to professional
and personal proxies
Not all studies included the option of a professional acting
as proxy, and it was not clear whether the person could
take part in the study if no personal proxy was able or will-
ing to be involved. In spite of the shared legal basis of per-
sonal and professional proxies, some studies appeared to
differentiate between them. This extended to consent forms
for two clinical trials that both visually and in terms of con-
tent differed significantly from standard consent forms used
in research, where the appearance was consistent with a let-
ter and did not contain individual statements or boxes to
be initialled, and no counter signature was required from
the person obtaining consent (ID 09, ID 23). Unlike the
personal legal representative consent forms, they did not
include similar statements about providing consent for ac-
cess to medical notes by the research sponsor or other rep-
resentatives ((ID 09, ID 23) or consent to obtain a blood
sample for analysis for the study and retention for future
related studies (ID 09). For one study there was no infor-
mation sheet for professional legal representatives, and in
place of a consent form there was a small section to be
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completed on the baseline case report form (ID 24). In a
second study there was also no information sheet for the
nominated consultee, and the ‘Registered Medical Practi-
tioner form’ did not mention ‘consultee’ or refer to advice
regarding the person’s wishes and feelings and had only two
statements, one of which was that they had no objection
and were not aware of any objections to the participant be-
ing enrolled in the study (ID 30). One information sheet for
professional legal representatives listed the inclusion and
exclusion criteria as well as details about the dose of the
medicinal product being investigated, its preparation and
administration, and trial unblinding procedures, whereas
the equivalent for a personal legal representative did not
(ID 19).
Inaccurate interpretation of the law
Some study documents conflicted with the regulatory
frameworks through inaccurate interpretation of the le-
gislation. This included statements such as ‘When deter-
mining who is able to provide such consent, the
Medicines for Human Use Regulations state that the in-
dividuals’ parents should always be approached first’ for
a trial involving adults only (ID 01). The CTR do not
specify which family members or friends, or in what
hierarchical order, the researcher should approach to act
as legal representative [6]. Another instance included the
requirement that mental capacity assessment be under-
taken on all potential participants, during which specific
details needed to be recalled by the person (a care home
resident) prior to being deemed to have capacity to pro-
vide informed consent for the study (ID 05). The MCA
clearly states that a person must be assumed to have
capacity unless it is established that they lack capacity;
this is a key principle of the Act (s1(2)) [5]. Other stud-
ies incorrectly stated the legal basis for the proxy’s deci-
sion, such as they are required to ‘assess whether study
enrolment is in the patient’s best interest’ (ID 19). Whilst
the MCA has as one of the underlying principles that
‘An act done, or decision made, under this Act for or on
behalf of a person who lacks capacity must be done, or
made, in his best interests’ (s1(5)) [5], the exception to
this is regarding decisions about research (s2.12) [23].
Discussion
This study examined study documents provided to con-
sultees and legal representatives who are involved in de-
cisions about research participation on behalf of an adult
who lacks capacity to consent. Although there are im-
portant conceptual differences between providing con-
sent for ourselves and on behalf of another, the results
from this study supported previous research that found
that many study documents lack items deemed to be im-
portant for promoting high-quality decisions [12, 24]. A
lack of information about the proxy’s role and the legal
basis for his/her decision risks failing to meet the re-
quirements for decisions about research participation to
be fully informed, and may therefore threaten the ethical
conduct of such research [25]. The database search in
this study also confirmed findings from other studies
that only very small numbers of studies include people
who lack capacity [3, 26, 27].
All included studies could recruit participants both
with and without capacity and had study documents for
the participant themselves if appropriate (these docu-
ments were not included in the study documents ana-
lysed). The length of information sheets varied
considerably. Although CTIMP information sheets were
longer than those for non-CTIMP studies (median num-
ber of words 2067 compared to 1602), as found in other
studies [28], the content that related to the role of the
proxy in CTIMPs was nearly half that provided in
non-CTIMPs (median number of words 232 compared
to 422). Information sheets for professionals acting as
proxy (median number of words 1610) were shorter than
those for personal proxies (1698 words) and for profes-
sionals and personal proxies jointly (1788 words).
All studies had received Research Ethics Committee
(REC) approval, and either they were currently recruiting
participants or recruitment had been completed. Despite
this, issues with incorrect terminology were common. This
suggests that issues identified in a study which was con-
ducted shortly after the introduction of the MCA, where
the legal requirements for research involving incapacitated
adults were not being consistently or correctly interpreted
by researchers and RECs [29], are largely unchanged in the
decade since. This lack of clarity may contribute to the con-
fusion and lack of understanding about the legislation by
health and social care professionals [30], leading to the ex-
clusion from research of those who lack capacity [4]. The
discrepancy between the legislatory requirements and the
research practice as a result of inaccurate interpretation of
the law is also significant, as it may affect the identification
and involvement of the correct proxy in the
decision-making process and interfere with the appropriate
legal and ethical basis for that decision.
Information sheets varied considerably in the content
relating to how the proxy should make a decision, with
21 studies not providing any such information across a
total of 29 documents. Four of the information sheets
did not provide information about withdrawing the per-
son from participating, and a further two provided it to
the personal proxy only and not the professional acting
as proxy (ID 19, ID 23). These two studies involved the
participant being followed up for 28 days. Requesting
withdrawal is a key part of the proxy’s role throughout
the whole duration of a participant’s involvement in a
study (s32(5)) [5], although it was included as a state-
ment in the consent form for one of the two studies (ID
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19). Some studies did inform proxies that the re-
searchers would seek consent from the participant once
(or if ) they regained capacity or from relatives/friends in
the interim, but this risks leaving the patient without
anyone to represent him/her in the intervening period.
The few documents which advised that the patient
should be involved in the decision were from studies be-
ing conducted with older people living in care homes.
People living with dementia, which affects around 69%
of care home residents [31, 32], may experience greater
fluctuation and variation in decision-making capacity
[33] compared to the populations included in other
studies, although all adults lacking capacity should be
supported and involved in decisions that concern them
as far as is possible [23, 34]. Under the CTR, the person
lacking capacity must have ‘received information accord-
ing to his capacity of understanding regarding the trial,
its risks and its benefits’ [6]. Although arguably this
might form part of the researcher’s obligation, in general
the study documents do not identify the need to inform
the persons lacking capacity about the trial or to include
them in the decision.
Disparities were seen between documents for profes-
sionals acting as proxy and those for relatives/friends, par-
ticularly in acute and critical care studies. The role of the
professional representative was distinguished from that of
the personal proxy in several of the studies, both in the
amount and content of the information provided to them
and in how their consent or advice was sought and docu-
mented. This role was ‘medicalised’ in some settings (not-
ably in critical care studies), where it was treated more
like a consultation for a second medical opinion about the
patient’s suitability and eligibility for the study rather than
an attempt to represent the person’s wishes and feelings
about taking part. This resulted in a conflation of profes-
sionals’ clinical and representation roles, which may be
due to the difficulty fulfilling the legal requirement for
representing the ‘presumed will’ of a person who is uncon-
scious or has significantly impaired capacity in an acute or
critical care setting where no previous relationship exists
between the healthcare professional and patient. This was
in contrast to studies in care home settings, where the
professional acting as proxy is likely to have developed a
close relationship with the person in their care, allowing
them to more fully represent the person’s current, if not
past, wishes and feelings about being part of a research
study. Studies consistently failed to address the complex
issue of how the proxy would be able to represent the per-
son’s wishes and feelings if such wishes had never been
expressed. These may be intractable questions due to the
nature of the requirements of the current legislation.
There is currently no HRA information sheet template for
clinical trials which fall under the CTR in the UK [9].
There appeared to be a disconnect between the concep-
tualisation of advance decisions under the MCA and the
wording used in the documents, which was based on the
HRA template information sheet [9]. This was seen both
in terms of differences in scope, as the MCA provisions
relate specifically to ADRTs) only [5], and because the
negative orientation towards treatment options under the
MCA means that an ADRT would be relevant only to
studies involving the treatment that was being refused and
not refusal of research in general. Only one study (ID 02)
mentioned the role of a Lasting Power of Attorney (LPA)
for health and welfare or a Court of Protection-appointed
Deputyship who would be involved in decisions about
care and treatment on behalf of a person with impaired
capacity. However, the role of an LPA or Deputy in deci-
sions about research remains unclear [35].
Strengths and limitations
To the best of our knowledge, no previous studies have
examined the information provided to proxies who are
involved in decision-making about research participation
by adults lacking capacity. Studies involving different
populations and study designs were included in order to
represent a range of contexts in which proxy
decision-making occurs. Content analysis allowed a
comprehensive understanding of both the study docu-
ments’ content and context.
The searches were conducted using one database
which is not necessarily intended for searches of this na-
ture; therefore, the search for eligible studies is by no
means considered exhaustive. Studies could only be in-
cluded where the documents were publicly available or
where the investigators were willing to share the docu-
ments, and therefore selection bias may have been intro-
duced. Documents could not be obtained for studies
where the research team was uncontactable. This oc-
curred because contact details were not listed on the
UKCTG and could not be obtained using Internet
searches, contact details were not operational, or there
was no response from all identifiable study contacts.
There were no refusals to provide study documents.
A further limitation is that a relatively small sample of
studies was reviewed, although this represented 43% of
the potentially eligible studies identified during the
searches. Very small numbers of CTIMPs were found, and
none of the included studies was sponsored or conducted
by pharmaceutical companies. Most studies were publicly
funded by the UK Department of Health and Social Care
through the NIHR, the research arm of the NHS. Study
populations did not include those participating in research
involving end-of-life care or mental illness. The findings
may not be representative of all study populations where
participants may have impaired capacity. Study documents
were limited to those used for participants in England and
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Wales only. Documents provided to participants in other
areas of the UK (Scotland and Northern Ireland) will differ
due to different legislation regarding research involving
adults who lack capacity [36, 37], except clinical trials of
medicinal products, which are regulated by UK-wide legis-
lation [6].
An important limitation is that only written informa-
tion was analysed in this study, which forms only one
‘piece of the jigsaw’ of decision-making [12]. In practice,
information sheets are provided in addition to an inter-
view with the research team, during which proxies will
receive further information which may be tailored to
their information and decision-making needs. Studies
also used other forms of communicating with patients
and proxies, such as providing brief or easy-read infor-
mation to enhance the ability of the person with im-
paired capacity to understand study information and be
supported to provide their own consent, or obtaining
verbal consent where research was conducted following
a medical emergency.
Recommendations for future research
In-depth exploration of proxies’ information needs and
decision-making processes may allow a greater under-
standing of how proxies are prepared for, and undertake,
decision-making in practice. Observation of consulta-
tions with proxies, and proxies’ accounts of experiences
of being consulted, including issues influencing their de-
cisions, will provide additional information about proxy
decision-making for research, which is currently poorly
understood. This may assist in developing a minimum
standard of information provision or evidence-based
content which, if evaluated, would allow optimised writ-
ten information to be provided by researchers. This
would help ensure that proxies are fully informed about
their role, enhance the consultation process with prox-
ies, and support high-quality decision-making and the
provision of truly informed consent where appropriate.
The development of interventions to inform and sup-
port those who design and conduct research studies
which include adults lacking capacity, as well as those
responsible for the ethical review of such studies, may
be warranted.
Recommendations for research practice
To improve comprehension and uncertainty for all those
involved in research with adults lacking capacity, there is
a need for accuracy in the use of terms for consultees
and legal representatives by researchers in study docu-
ments. There needs to be greater clarity around the role
of both personal and professional consultees and legal
representatives, the basis for their decision, and whether
they are being asked for consent or advice. Researchers
may benefit from engaging with individuals or
institutions with legal and ethical expertise when devel-
oping study documents involving populations where
consent and recruitment may be complex. Consistency
in the review of information sheets and consent/declar-
ation forms by RECs could reduce the level of inaccur-
acy and, as a result, may reduce the confusion and
misunderstanding for those either seeking or providing
informed consent or advice for research participation.
To ensure compliance with the legal requirements, and
following the principles of informed consent, information
sheets should include sufficient information to allow prox-
ies to understand why they are being approached and the
basis on which they should make a decision. Orientating
the proxy to making a decision based on what the patient
himself would have decided, rather than the proxy’s own
personal views about research in general or the particular
study in question, may be of benefit. Ensuring the proxy is
informed about his/her role in withdrawing the person
from the study, should the proxy feel the person would
wish to withdraw from it, should be clearly stated and ar-
rangements made to ensure the person remains repre-
sented at all times. It is important that this does not
contribute to an increase in the length of study docu-
ments. Using a ‘layered’ or ‘tiered’ approach to informa-
tion provision can avoid overwhelming potential
participants with lengthy and complicated PISs, whilst
providing accurate and relevant information to ensure
genuinely informed consent [38]. A ‘layered’ approach in-
volves initially providing potential participants with a
short summary including sufficient information needed to
decide whether or not to take part in the research, with
user-friendly methods of access to more detailed informa-
tion presented in one or more additional layers [38]. The
primary information should clearly explain how this fur-
ther information may be accessed [38].
Further guidance for researchers when drafting docu-
ments for studies involving adults lacking capacity is rec-
ommended, particularly for clinical trials of medicinal
products where template documents may be of benefit,
and where professionals in acute and critical care settings
are involved as consultees or legal representatives. Given
their development of other template documents and guid-
ance, it may be appropriate for the HRA to develop this
template, utilising the findings from this study. Given the
difficulties of representing the wishes and feelings of those
whose wishes are unknown or could never be known,
there may be a need to re-examine the legal basis for
proxy decision-making in research for these populations.
Conclusions
This study has examined the written information cur-
rently provided to family members, friends, and health
and social care professionals involved in decisions about
research on behalf of a person with impaired capacity.
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Existing study documents had ethical approval, yet many
used inaccurate terms and lacked essential information,
and some studies had incorrectly interpreted legal provi-
sions. Particular issues were seen with the information
provided to professionals acting as proxy in acute and
critical care settings, where the clinical and representa-
tion roles were conflated. Whilst written information is
usually accompanied by verbal explanation and supple-
mentary information, the findings suggest that proxy deci-
sions about research participation may not be sufficiently
informed to meet the legal and ethical requirements.
Future research practice should focus on ensuring ad-
equate information is provided to proxies in order for an
informed decision to be made, thereby ensuring compliance
with the legal frameworks. Further research is needed to
explore the information and decision-making needs of
those acting as proxies. There is a need to clarify the role of
advance decisions and LPA in research and to re-examine
the legal basis for decisions for those for whom there is no
evidence of their wishes and feelings about research partici-
pation. These endeavours should focus on mechanisms for
appropriate inclusion in research, and they should not be at
the expense of further exclusion from research for these
under-represented populations.
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